Drugs / MINT1526A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01139723 | Jun 2010 → Aug 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MINT1526A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01139723 ↗ |
| Known as | RG-7594 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298044 ↗ |
| Route | Intravenous | “MINT1526A administered alone and in combination with bevacizumab by IV infusion” NCT01139723 ↗ |